Skip to main content
. 2016 Jul 14;2016:3204083. doi: 10.1155/2016/3204083

Table 2.

Baseline and posttreatment endocrine and metabolic parameters of groups A and B of PCOS patients.

 Group A (n = 21)  Group B (n = 25)
Baseline MI plus DCI p value Baseline placebo p value
FSH (mIU/mL) 5.86 ± 1.75 4.96 ± 1.74 ns 5.67 ± 1.11 5.47 ± 0.63 ns
LH (mIU/mL) 12.5 ± 8 8.5 ± 4.04 p < 0.05 11.27 ± 7.2 11.25 ± 5.35 ns
E (pg/mL) 47.06 ± 18.20 107.42 ± 92.86 p < 0.01 50.37 ± 19.45 52 ± 20.2 ns
Fasting insulin (μU/mL) 20.19 ± 8.14 10.74 ± 5.46 p < 0.001 18 ± 8 17.8 ± 8.2 ns
Fasting glucose (mg/dL) 85 ± 5.96 86 ± 7.12 ns 86.2 ± 9.1 84.73 ± 8.3 ns
Free testosterone (ng/dL) 0.76 ± 0.20 0.62 ± 0.15 p < 0.05 0.85 ± 0.22 0.83 ± 0.2 ns
SHBG (nmol/L) 24.11 ± 10.35 35.85 ± 24.3 p < 0.05 20.44 ± 8.77 21.36 ± 7.57 ns
Androstenedione (ng/mL) 4.25 ± 1.48 4.01 ± 1.70 ns 3.48 ± 1.21 3.12 ± 2.23 ns
DHEAS (μg/dL) 327.32 ± 150.89 347.6 ± 170.98 ns 337.95 ± 155.79 315.83 ± 145.59 ns
HOMA 3.38 ± 1.97 1.97 ± 1.48 p < 0.05 3.48 ± 2.02 2.8 ± 1.4 ns

E, 17-beta-Estradiol; P, progesterone; 17OHP, 17-OH-progesterone; SHBG, Sex Hormone Binding Globulin; DHEAS, dehydroepiandrosterone sulphate.